Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Trial Profile

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms RUXO-BEAT
  • Most Recent Events

    • 05 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 07 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top